Management
Martin McGlynn, President and Chief Executive Officer
Martin McGlynn joined StemCells, Inc. in January of 2001 as President and Chief Executive Officer and was elected to our Board of Directors on February 6, 2001. Mr. McGlynn has spent several decades in the life sciences industry in Europe, Canada and the United States. He began his career with Becton Dickinson, Ireland Ltd., and spent eight years in manufacturing operations. He joined Abbott Labs in 1977 where he held positions as General Manager, Abbott Ireland Ltd., President and General Manager of Abbott Canada Ltd. and Vice President of Abbott International Ltd. In 1990, he joined the BOC Group as President of Anaquest, Inc., a global leader in anesthesia and acute care pharmaceuticals headquartered in New Jersey. Mr. McGlynn joined the biotech industry in 1994 when he became President and Chief Executive Officer of Pharmadigm, Inc., a private, venture capital-backed company engaged in the research and development of a new class of anti-inflammatory agents. Mr. McGlynn is a native of Dublin, Ireland. He holds a Bachelor of Commerce degree from University College, Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries (CII) and the Pharmaceutical Manufacturers Association of Canada (PMAC).
ˆTop
Ann Tsukamoto, Ph.D., Chief Operating Officer
Ann Tsukamoto, Ph.D., was appointed Chief Operating Officer in November 2006. Prior to that, she served as Vice President, Research and Development. Dr. Tsukamoto has ~20 years experience in stem cell biology and was a co-discoverer of the human hematopoietic stem cell while at SyStemix, Inc., and she played a leading role in the launch of the clinical research program for the hematopoietic stem cell. Under her direction at StemCells Inc., the scientific team has discovered the human central nervous system stem cell, a population of human liver engrafting cells and a candidate pancreas stem cell. Dr. Tsukamoto received her Ph.D. from the University of California, Los Angeles and did postdoctoral research with Dr. Harold Varmus at the University of California, San Francisco where she worked on the wnt-1 gene, which is a key player in the stem cell self-renewal pathway. Dr. Tsukamoto is an inventor on six issued U.S. patents related to the human hematopoietic stem cell.
ˆTop
Rodney Young, Chief Financial Officer & VP, Finance and Administration
Rodney Young joined StemCells, Inc. in September 2005. He is responsible for the financial and administrative functions of the Company, as well as for managing investor relations and the Company's overall relationship with the financial community. Mr. Young was formerly Chief Financial Officer and a Director of Extropy Pharmaceuticals, Inc., a private pharmaceutical company focused on developing drugs for pediatric indications, where he was responsible for all financial and administrative functions. Before joining Extropy, Mr. Young was Managing Director and head of healthcare corporate finance in Europe for SG Cowen Securities, and prior to that, he spent more than a decade at Lehman Brothers, where he was a senior investment banker in both the healthcare and mergers & acquisitions groups. Mr. Young earned his BA and MBA degrees from the University of Chicago.
ˆTop
Stephen Huhn, M.D., F.A.C.S., F.A.A.P., VP, Head of the Neural Program
Dr. Stephen Huhn joined StemCells, Inc. in January 2007 to direct the Company's pre-clinical and clinical development programs for CNS indications. He is on leave from Stanford University School of Medicine, where he is Associate Professor of Neurosurgery and Chief of Pediatric Neurosurgery. Dr. Huhn earned his M.D. at the University of Arizona College of Medicine and completed his neurosurgery residency at the University of Maryland Medical System. He also held a neuro-oncology fellowship at UCSF Medical Center in San Francisco and a pediatric neurosurgery fellowship at Northwestern Children's Memorial Hospital in Chicago. He is certified by the American Board of Pediatric Neurological Surgery and the American Board of Neurological Surgery.
ˆTop
Elizabeth Leininger, Ph.D., VP, Regulatory Affairs and Quality Assurance
Elizabeth Leininger, Ph.D., joined StemCells, Inc. in April 2006 and manages global regulatory affairs, including tissue acquisition and cell processing regulatory issues. Prior to joining StemCells, she worked as vice president of regulatory affairs and quality at BAS Medical, where she was responsible for quality assurance, and regulatory strategy and submissions. Her prior experience includes working at Biologics Consulting Group, GlaxoSmithKline and Chiron Corporation, as well as the U.S. Food and Drug Administration. Dr. Leininger earned her Ph.D. in chemistry from the University of North Carolina at Chapel Hill.
ˆTop
Maria Millan, M.D., F.A.C.S., VP, Head of the Liver Program
Dr. Maria Millan joined StemCells, Inc. in January 2006 and was promoted to Vice President, Head of the Liver Program in December 2006. She is responsible for managing the pre-clinical and clinical development programs for liver indications. Dr. Millan is also serving as the Company's Acting Chief Medical Officer. She is on leave from her positions as Associate Professor of Surgery, Division of Multi-Organ Transplant, and Director of Pediatric Transplant Programs, Kidney & Liver, at Stanford University School of Medicine. She received her M.D. from the New Jersey Medical School and was a Resident and Chief Resident in General Surgery at Harvard Medical School/New England Deaconess Hospital and the Beth Israel Deaconess Medical Center in Boston, Mass. She received a research fellowship in Immunobiology at Harvard Medical School, and held a Fellowship in Multi-Organ Transplant Surgery at Stanford Medical School.
ˆTop
Ken Stratton , General Counsel
Ken Stratton joined StemCells, Inc. as General Counsel in February 2007. His primary responsibilities include overseeing the Company’s legal operations and advising the Company and its management and directors on various compliance matters. He also serves as corporate secretary. Mr. Stratton was formerly Deputy General Counsel at Threshold Pharmaceuticals, Inc., and prior to that was Senior Legal Counsel for the vascular business unit of Medtronic, Inc., an international medical device manufacturer. Prior to joining industry, Mr. Stratton was a business attorney in private practice for ten years handling both transactional and litigation matters with corporate law firms in San Francisco and Palo Alto. He earned both his J.D. and M.B.A. in finance from New York University and his B.A. from the University of Pennsylvania.
ˆTop
Nobuko Uchida, Ph.D., VP, Stem Cell Biology
Dr. Nobuko Uchida is responsible for the Company's discovery initiative focusing on identifying new stem or progenitor cells, as well as for characterizing the Company's human neural stem cell and candidate liver and pancreas stem cells. Dr. Uchida has been with the Company since 1998, and in 1999 she was first to identify, by cell surface marker, the human central nervous system stem cell. Dr. Uchida was previously employed at SyStemix, Inc. as a Research Scientist working on hematopoietic stem cell biology, and has worked in stem cell biology for the past 15 years. Dr. Uchida obtained her Ph.D. in Cancer Biology from Stanford University and completed her post doctoral training in the laboratory of Dr. Irving Weissman at the Stanford University School of Medicine.
ˆTop
|
|
